TY - JOUR
T1 - MIL-100(Fe)-Enabled Oral Delivery of Syringic Acid with Enhanced Pharmacokinetics
AU - Santos, Joshua H.
AU - Victoriano, Hannah Jean
AU - Sepulveda, Mary
AU - Liu, Hung En
AU - Valencia, Shierrie Mae N.
AU - Walde, Rikkamae Zinca Marie L.
AU - Ongo, Emelda A.
AU - Lin, Chia Her
N1 - Publisher Copyright:
© 2025 by the authors.
PY - 2025/10
Y1 - 2025/10
N2 - Background/Objectives: Plant-derived bioactive compounds like syringic acid, a phenolic acid from the shikimic acid pathway, have shown potential against chronic diseases, including diabetes, cardiovascular disorders, cancer, and cerebral ischemia. However, its poor water solubility and rapid systemic elimination result in low oral bioavailability, limiting therapeutic potential. This study aimed to enhance its oral bioavailability using MIL-100(Fe), a metal–organic framework (MOF) known for high surface area and drug-loading capacity. Methods: MIL-100(Fe) was synthesized using an optimized method and loaded with syringic acid through impregnation at 12, 24, 36, and 48 h. Characterization included PXRD, FTIR, BET, SEM, and DLS. Acute oral toxicity was evaluated following OECD 423 guidelines, and bioavailability was assessed in Sprague Dawley rats. Results: The 1:2 MIL-100(Fe) to syringic acid ratio achieved the highest drug loading at 64.42 ± 0.03% (12 h). PXRD and FTIR confirmed successful loading (notably at 1239.2 cm−1), and TGA indicated thermal stability at ~350 °C. SEM revealed octahedral particles with an average size of 270.67 ± 2.60 nm. BET showed reduced surface area post-loading. In vitro drug release exhibited media-dependent profiles. Toxicity tests indicated no adverse effects at 2000 mg/kg. Oral administration of SYA@MIL-100(Fe) resulted in a 10.997-fold increase in relative bioavailability versus oral syringic acid and a 12.82-fold increase compared to intraperitoneal administration. Conclusions: MIL-100(Fe) is a safe and effective oral carrier for syringic acid, significantly enhancing its bioavailability. This platform shows strong potential for delivering phenolic compounds in pharmaceutical applications.
AB - Background/Objectives: Plant-derived bioactive compounds like syringic acid, a phenolic acid from the shikimic acid pathway, have shown potential against chronic diseases, including diabetes, cardiovascular disorders, cancer, and cerebral ischemia. However, its poor water solubility and rapid systemic elimination result in low oral bioavailability, limiting therapeutic potential. This study aimed to enhance its oral bioavailability using MIL-100(Fe), a metal–organic framework (MOF) known for high surface area and drug-loading capacity. Methods: MIL-100(Fe) was synthesized using an optimized method and loaded with syringic acid through impregnation at 12, 24, 36, and 48 h. Characterization included PXRD, FTIR, BET, SEM, and DLS. Acute oral toxicity was evaluated following OECD 423 guidelines, and bioavailability was assessed in Sprague Dawley rats. Results: The 1:2 MIL-100(Fe) to syringic acid ratio achieved the highest drug loading at 64.42 ± 0.03% (12 h). PXRD and FTIR confirmed successful loading (notably at 1239.2 cm−1), and TGA indicated thermal stability at ~350 °C. SEM revealed octahedral particles with an average size of 270.67 ± 2.60 nm. BET showed reduced surface area post-loading. In vitro drug release exhibited media-dependent profiles. Toxicity tests indicated no adverse effects at 2000 mg/kg. Oral administration of SYA@MIL-100(Fe) resulted in a 10.997-fold increase in relative bioavailability versus oral syringic acid and a 12.82-fold increase compared to intraperitoneal administration. Conclusions: MIL-100(Fe) is a safe and effective oral carrier for syringic acid, significantly enhancing its bioavailability. This platform shows strong potential for delivering phenolic compounds in pharmaceutical applications.
KW - AUC
KW - bioavailability
KW - MIL-100(Fe)
KW - MOF
KW - syringic acid
UR - https://www.scopus.com/pages/publications/105020044800
UR - https://www.scopus.com/pages/publications/105020044800#tab=citedBy
U2 - 10.3390/pharmaceutics17101282
DO - 10.3390/pharmaceutics17101282
M3 - Article
AN - SCOPUS:105020044800
SN - 1999-4923
VL - 17
JO - Pharmaceutics
JF - Pharmaceutics
IS - 10
M1 - 1282
ER -
